A phase II study with rucaparib, which is also an oral PARP inhibitor, focused on the efficacy and safety of rucaparib in BRCA-mutated patients with measurable locally advanced, metastatic, pancreatic cancer [79]. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.